Autologous Bone Marrow Mononuclear Cells(Cryopraxis Criobiologia Ltda)(Autologous Bone Marrow Mononuclear Cells(Cryopraxis Criobiologia Ltda))

概要

基本信息

药物类型

细胞疗法

别名-

靶点-

作用机制

细胞替代物

治疗领域

神经系统疾病心血管疾病

在研适应症-

非在研适应症

冠心病围手术期缺血难治性心绞痛

原研机构

Cryopraxis Criobiologia Ltda.

在研机构-

非在研机构

CellPraxis Bioengenharia Ltda.

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

6

项与 Autologous Bone Marrow Mononuclear Cells(Cryopraxis Criobiologia Ltda) 相关的临床试验

ChiCTR2000035269 / Recruiting早期临床1期IIT

EUS-guided intraportal infusion of autologous bone marrow in patients with decompensated liver cirrhosis

开始日期2018-12-27

申办/合作机构

中南大学湘雅三医院

JPRN-jRCTb051200014 / Completed临床2期IIT

Treatment for spinal cord injury patients (ASIA A, B) using autologous bone-marrow mononuclear cells - Phase 2 clinical study - Treatment for spinal cord injury patients with bone-marrow mononuclear cells

开始日期2016-11-28

申办/合作机构-

JPRN-UMIN000007599 / Completed临床1/2期IIT

Phase 1/2 study of treatment for spinal cord injury with autologous mononuclear cells derived from bone marrow - Phase 1/2 study of treatment for spinal cord injury with autologous mononuclear cells derived from bone marrow

开始日期2012-03-01

申办/合作机构-

100 项与 Autologous Bone Marrow Mononuclear Cells(Cryopraxis Criobiologia Ltda) 相关的临床结果

登录后查看更多信息

100 项与 Autologous Bone Marrow Mononuclear Cells(Cryopraxis Criobiologia Ltda) 相关的转化医学

登录后查看更多信息

100 项与 Autologous Bone Marrow Mononuclear Cells(Cryopraxis Criobiologia Ltda) 相关的专利（医药）

登录后查看更多信息

5

项与 Autologous Bone Marrow Mononuclear Cells(Cryopraxis Criobiologia Ltda) 相关的文献（医药）

2017-12-01·BMC Pediatrics4区 · 医学

Outcomes of autologous bone marrow mononuclear cells for cerebral palsy: an open label uncontrolled clinical trial

4区 · 医学

ArticleOA

作者: Ngo, Doan V ; Nguyen, Liem Thanh ; Vu, Chinh Duy ; Bui, Anh V ; Nguyen, Anh Tuan

BACKGROUNDStem cell therapy has emerged as a promising method for improving motor function of patients with cerebral palsy. The aim of this study is to assess the safety and effectiveness of autologous bone marrow mononuclear stem cell transplantation in patients with cerebral palsy related to oxygen deprivation.METHODSAn open label uncontrolled clinical trial was carried out at Vinmec International Hospital. The intervention consisted of two administrations of stem cells, the first at baseline and the second 3 months later. Improvement was monitored at 3 months and 6 months after the first administration of stem cells, using the Gross Motor Function Measure (GMFM) and Modified Ashworth Score which measures muscle tone.RESULTSNo severe complications were recorded during the study. After transplantation, 12 patients encountered fever without infections and 9 patients experienced vomiting which was easily managed with medications. Gross motor function was markedly improved 3 months or 6 months after stem cell transplantation than at baseline. The post-transplantation GMFM-88 total score, each of its domains and the GMFM-66 percentile were all significantly higher (p-value < 0.001). Muscle spasticity also reduced significantly after transplantation (p-value < 0.001). The therapy was equally effective regardless of sex, age and GMFCS level (p-value > 0.05).CONCLUSIONAutologous bone marrow mononuclear cell transplantation appears to be a safe and effective therapy for patients with cerebral palsy.TRIAL REGISTRATIONClinicalTrials.gov Identifier: NCT02569775 . Retrospectively registered on October 15, 2015.

2016-11-01·EBioMedicine1区 · 医学

Autologous Stem Cell Transplantation Promotes Mechanical Stretch Induced Skin Regeneration: A Randomized Phase I/II Clinical Trial

1区 · 医学

ArticleOA

作者: Wang, Jing ; Gan, Yao-Kai ; Li, Qing-Feng ; Gu, Bin ; Zhou, Shuang-Bai ; Magee, William P ; Chiang, Cheng-An ; Yao, Caroline A ; Zhang, Guo-You ; Li, Hua ; Zan, Tao ; Yang, Mei ; Xie, Feng ; Xie, Yun ; Pu, Lee Q ; Liu, Kai ; Zhou, Jia

BACKGROUNDMechanical stretch, in term of skin expansion, can induce effective but limited in vivo skin regeneration for complex skin defect reconstruction. We propose a strategy to obtain regenerated skin by combining autologous stem cell transplantation with mechanical stretch.METHODSThis randomized, blinded placebo-controlled trial enrolled 38 adult patients undergoing skin expansion presenting with signs of exhausted regenerative capacity. Patients randomly received autologous bone marrow mononuclear cell (MNC) or placebo injections intradermally. Follow-up examinations were at 4, 8weeks and 2years. The primary endpoint was the volume achieved in relation to the designed size of the expander (expansion index, EI). Secondary endpoints were surface area, thickness and texture of expanded skin. This trial is registered with ClinicalTrial.gov, NCT01209611.FINDINGSThe MNC group had a significantly higher EI at 4weeks (mean difference 0.59 [95% CI, 0.03-1.16]; p=0.039) and 8weeks (1.05 [95% CI, 0.45-1.66]; p=0.001) versus controls. At 8weeks, the MNC group had significantly thicker skin (epidermis: p<0.001, dermis: p<0.001) and higher subjective scores for skin quality/texture (24.8 [95% CI, 17.6-32.1]; p<0.001). The MNC group had more skin surface area (70.34cm² [95% CI, 39.75-100.92]; p<0.001). Patients in the MNC group gained up to the quadrupled surface area of expanded skin compared to pre-expansion at the end of expansion. No severe adverse events occurred.INTERPRETATIONIntradermal transplantation of autologous stem cells represents a safe and effective strategy to promote in vivo mechanical stretch induced skin regeneration, which can provide complex skin defect reconstruction with plentiful of tissue.

2008-07-15·Annals of the Academy of Medicine, Singapore4区 · 医学

Autologous Bone Marrow Plasma Injection after Arthroscopic Debridement for Elbow Tendinosis

4区 · 医学

Article

作者: Moon, Young Lae ; Jang, Soo Jeong ; Lee, Hyun Ju ; Park, Geon ; Jo, Sueng-Hwan ; Song, Chang Hun

Introduction: The treatment of tendinosis of elbow can be challenging, yet rewarding. Nevertheless, for the patients who failed conservative management and develop persistent recalcitrant symptoms, surgical intervention should be considered. The hypothesis of this study is iliac bone marrow plasma injection after arthroscopic debridement of degenerative tissue will bring along biological cure. Thus, it will not only reduce pain but also improve function in patients with resistant elbow tendonitis. Materials and Methods: Twenty-four patients (26 elbows) with significant persistent pain for a mean of 15 months, despite of standard rehabilitation protocol and a variety of other nonsurgical modalities were treated arthroscopically. We applied autologous iliac bone marrow plasma injection following arthroscopic debridement. This material is produced by centrifugation of iliac bone marrow blood at 1,800 rpm for 20 to 30 minutes. Patients were allowed full range of motion (ROM) exercise after 2 to 3 days. Cytokine analyses for this injective material were done. Outcome was rated by postoperative sonography, visual analog pain scores (VAS) and Mayo elbow performance scores (MEPS) at 8 weeks and 6 months follow-up. Informed consent had been obtained from the subjects, and the study protocol was approved by the ethics committee of Chosun University Hospital, Korea. Results: All patients in this study noted improvement both in their VAS and MEPS. No complication occurred in any patient. Evidence of tendon healing was observed in postoperative songraphic examination. Predominant cytokines of this study were interleukin-12 (IL-12), interferon-gammainducible protein-10 (IP-10) and RANTES. Conclusion: Biologic treatments in orthopaedics are just beginning to evolve. In the present investigation, the injection of iliac bone marrow plasma after arthroscopic debridement in severe elbow tendinosis demonstrated early recovery of daily activities and clear improvement. Keywords: Epicondylitis, Iliac bone marrow plasma, Tendinosis

100 项与 Autologous Bone Marrow Mononuclear Cells(Cryopraxis Criobiologia Ltda) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
冠心病	临床2期	巴西	CellPraxis Bioengenharia Ltda.	2005-07-31
围手术期缺血	临床2期	巴西	CellPraxis Bioengenharia Ltda.	2005-07-31
难治性心绞痛	临床2期	巴西	CellPraxis Bioengenharia Ltda.	2005-07-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01966042 (ReACT, CTgov)	临床2期	难治性心绞痛	13	Autologous bone marrow mononuclear cells	鏇顧願顧構夢糧齋構築(蓋遞憲鏇獵廠繭壓獵夢) = 蓋範壓簾鹽膚膚鬱鏇製鏇餘獵糧製憲鬱衊簾獵 (艱淵壓艱築蓋構築願鹽, 構築觸網鑰觸顧選襯壓 ~ 鏇繭醖鹹鏇選鏇鏇廠鹹) 更多	-	2014-06-03